Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials
暂无分享,去创建一个
N. Eriksson | A. Siegbahn | G. Paré | F. Asselbergs | B. Mahmoodi | S. James | D. Claassens | J. T. ten Berg | K. Meijer | L. Wallentin | S. Ross | Daniel M. F. Claassens
[1] P. Deloukas,et al. Association of Factor V Leiden With Subsequent Atherothrombotic Events , 2020, Circulation.
[2] M. Postma,et al. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. , 2019, The New England journal of medicine.
[3] Yan V. Sun,et al. Subsequent Event Risk in Individuals With Established Coronary Heart Disease , 2019, Circulation. Genomic and precision medicine.
[4] P. Deloukas,et al. Impact of Selection Bias on Estimation of Subsequent Event Risk , 2017, Circulation. Cardiovascular genetics.
[5] Ni Chen,et al. Platelet‐Derived Factor V Is a Critical Mediator of Arterial Thrombosis , 2017, Journal of the American Heart Association.
[6] P. Wells,et al. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation. , 2017, The American journal of medicine.
[7] Marleen de Bruijne,et al. Comparison of CT and CMR for detection and quantification of carotid artery calcification: the Rotterdam Study , 2017, Journal of Cardiovascular Magnetic Resonance.
[8] M. Postma,et al. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. , 2014, American heart journal.
[9] E. Falk,et al. Mechanisms of plaque formation and rupture. , 2014, Circulation research.
[10] A. Folsom,et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls , 2013, European Journal of Epidemiology.
[11] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[12] S. Kathiresan,et al. The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease , 2010, Journal of thrombosis and haemostasis : JTH.
[13] S. Kittner,et al. Meta-Analysis of Factor V Leiden and Ischemic Stroke in Young Adults: The Importance of Case Ascertainment , 2010, Stroke.
[14] L. Smeeth,et al. Causal Relationship of Susceptibility Genes to Ischemic Stroke: Comparison to Ischemic Heart Disease and Biochemical Determinants , 2010, PloS one.
[15] G. Lippi,et al. Factor V Leiden and hemophilia. , 2010, Thrombosis research.
[16] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[17] R. Lange,et al. Factor V Leiden Does Not Affect Bleeding in Aprotinin Recipients after Cardiopulmonary Bypass , 2007, Anesthesiology.
[18] S. Yusuf,et al. Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.
[19] John Danesh,et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controls , 2006, The Lancet.
[20] M. Poncz,et al. Factor V Leiden improves in vivo hemostasis in murine hemophilia models , 2005, Journal of thrombosis and haemostasis : JTH.
[21] A. George,et al. Factor V Leiden Protects Against Blood Loss and Transfusion After Cardiac Surgery , 2003, Circulation.
[22] J. Corral,et al. Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage. , 2001, Blood.
[23] L. Kuller,et al. Factor V Leiden Is not a Risk Factor for Arterial Vascular Disease in the Elderly: Results from the Cardiovascular Health Study , 1998, Thrombosis and Haemostasis.
[24] P. Ridker,et al. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. , 1997, JAMA.
[25] P. Ridker,et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. , 1995, The New England journal of medicine.
[26] K. Sueishi,et al. Intimal neovascularization in human coronary atherosclerosis: its origin and pathophysiological significance. , 1995, Human pathology.
[27] Pieter H. Reitsma,et al. Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.
[28] K. Mann,et al. Radioimmunoassay of factor V in human plasma and platelets. , 1982, Blood.
[29] P. Kolh,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[30] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[31] P. R. R. Ecurrent,et al. EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .